ALLO-ASC-TI(Anterogen)(ALLO-ASC-TI(Anterogen))

概要

基本信息

药物类型

干细胞疗法

别名-

靶点-

作用机制

干细胞替代物

治疗领域

神经系统疾病皮肤和肌肉骨骼疾病其他疾病+ [2]

在研适应症-

非在研适应症

克罗恩病克罗恩病引起的肛周瘘网球肘

原研机构

Anterogen Co., Ltd.

在研机构-

非在研机构

Anterogen Co., Ltd.

最高研发阶段无进展临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 ALLO-ASC-TI(Anterogen) 相关的临床试验

NCT02131077 / Completed临床1/2期

A Multi-center, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase I/II Clinical Study to Evaluate Safety and Efficacy of Allogeneic Adipose-derived Stem Cells for the Treatment of Lateral Epicondylitis

The objective of this study is to evaluate the safety and efficacy of allogeneic adipose-derived stem cells (ALLO-ASC) in patients with lateral epicondylitis.

开始日期2014-01-01

申办/合作机构

Anterogen Co., Ltd.

KCT0000188 / Recruiting临床1期

A Phase I dose escalation clinical study to evaluate the safety and efficacy of ALLO-ASC(Allogenic adipose-derived stem cells) in the patients with Crohn's fistula.

开始日期2011-09-26

申办/合作机构

Anterogen Co., Ltd.

NCT01440699 / Completed临床1期

Phase I Study of Dose Escalation of Human Allogenic Adipose-derived Stem Cells (ALLO-ASC) to Evaluate Safety and Efficacy in Patients With Crohn's Fistula

Adipose-derived stem cells have properties of differentiation to various types of cells, immunomodulatory effects. adipose-derived stem cells (ASCs) show also low immunogenicity.
Anterogen has developed ANTG-ASC(Autologous ASC) which has shown good efficacy and safety in Phase I and II study on the patients with Crohn's fistula.
However, Crohn's patients are sometimes not fat enough to extract fat tissue for culturing ASCs. Therefore the investigators have planned to study allogenic ASCs for safety and efficacy in patients with Crohn's fistula.

开始日期2011-09-01

申办/合作机构

Anterogen Co., Ltd.

100 项与 ALLO-ASC-TI(Anterogen) 相关的临床结果

登录后查看更多信息

100 项与 ALLO-ASC-TI(Anterogen) 相关的转化医学

登录后查看更多信息

100 项与 ALLO-ASC-TI(Anterogen) 相关的专利（医药）

登录后查看更多信息

100 项与 ALLO-ASC-TI(Anterogen) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
网球肘	临床2期	韩国	Anterogen Co., Ltd.	2014-01-01
克罗恩病	临床1期	韩国	Anterogen Co., Ltd.	2011-09-01
克罗恩病引起的肛周瘘	临床1期	韩国	Anterogen Co., Ltd.	2011-09-01